Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents
Current treatments for acute myocardial infarction (AMI) have dramatically improved clinical outcomes during the first year after AMI. Less is known, however, about the subsequent risks of recurrent cardiovascular events and mortality in patients who survive 1 year after AMI. The purpose of the pres...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/16/3642 |
| _version_ | 1797523357380378624 |
|---|---|
| author | Sungmin Lim Eun Ho Choo Ik Jun Choi Kwan Yong Lee Su Nam Lee Byung-Hee Hwang Chan Joon Kim Mahn-Won Park Jong-Min Lee Chul Soo Park Hee-Yeol Kim Ki-Dong Yoo Doo Soo Jeon Ho Joong Youn Wook Sung Chung Min Chul Kim Myung Ho Jeong Hyeon Woo Yim Youngkeun Ahn Kiyuk Chang |
| author_facet | Sungmin Lim Eun Ho Choo Ik Jun Choi Kwan Yong Lee Su Nam Lee Byung-Hee Hwang Chan Joon Kim Mahn-Won Park Jong-Min Lee Chul Soo Park Hee-Yeol Kim Ki-Dong Yoo Doo Soo Jeon Ho Joong Youn Wook Sung Chung Min Chul Kim Myung Ho Jeong Hyeon Woo Yim Youngkeun Ahn Kiyuk Chang |
| author_sort | Sungmin Lim |
| collection | DOAJ |
| description | Current treatments for acute myocardial infarction (AMI) have dramatically improved clinical outcomes during the first year after AMI. Less is known, however, about the subsequent risks of recurrent cardiovascular events and mortality in patients who survive 1 year after AMI. The purpose of the present study is to evaluate long-term clinical outcomes in 1-year AMI survivors who were implanted with newer-generation drug-eluting stents (DESs) since 2010. The COREA-AMI (CardiOvascular Risk and idEntificAtion of potential high-risk population in AMI) registry consecutively enrolled AMI patients who underwent percutaneous coronary intervention (PCI), and patients who received newer-generation DESs since 2010 were analyzed. The primary endpoint was major adverse cardiovascular events (MACEs), and secondary endpoint was all-cause mortality. Of 6242 AMI patients, 5397 were alive 1 year after the index procedure. The cumulative incidence of MACEs and all-cause death 1 to 7 years after AMI were 28.4% (annually 4–6%) and 20.2% (annually 3–4%), respectively. Multivariate analysis showed that uncontrolled systolic blood pressure (SBP) and serum low-density lipoprotein cholesterol (LDL-C) concentration, as well as traditional risk factors, were associated with MACEs and all-cause death. Recurrent non-fatal myocardial infarction, ischemic stroke, and bleeding events within 1 year were significantly associated with all-cause death. The risks of adverse cardiovascular events and death remain high in AMI patients more than 1 year after the index PCI with newer-generation DESs. Traditional risk factors, uncontrolled SBP and LDL-C, and non-fatal adverse events within 1 year after the index procedure strongly influence long-term clinical outcomes. |
| first_indexed | 2024-03-10T08:41:48Z |
| format | Article |
| id | doaj.art-426e7ee7961c45669dd0dc5ec80d4688 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T08:41:48Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-426e7ee7961c45669dd0dc5ec80d46882023-11-22T08:11:23ZengMDPI AGJournal of Clinical Medicine2077-03832021-08-011016364210.3390/jcm10163642Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting StentsSungmin Lim0Eun Ho Choo1Ik Jun Choi2Kwan Yong Lee3Su Nam Lee4Byung-Hee Hwang5Chan Joon Kim6Mahn-Won Park7Jong-Min Lee8Chul Soo Park9Hee-Yeol Kim10Ki-Dong Yoo11Doo Soo Jeon12Ho Joong Youn13Wook Sung Chung14Min Chul Kim15Myung Ho Jeong16Hyeon Woo Yim17Youngkeun Ahn18Kiyuk Chang19Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, St Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, St Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University School of Medicine, Gwangju 61469, KoreaDivision of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University School of Medicine, Gwangju 61469, KoreaDepartment of Preventive Medicine, Clinical Research Coordinating Center, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDivision of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University School of Medicine, Gwangju 61469, KoreaDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaCurrent treatments for acute myocardial infarction (AMI) have dramatically improved clinical outcomes during the first year after AMI. Less is known, however, about the subsequent risks of recurrent cardiovascular events and mortality in patients who survive 1 year after AMI. The purpose of the present study is to evaluate long-term clinical outcomes in 1-year AMI survivors who were implanted with newer-generation drug-eluting stents (DESs) since 2010. The COREA-AMI (CardiOvascular Risk and idEntificAtion of potential high-risk population in AMI) registry consecutively enrolled AMI patients who underwent percutaneous coronary intervention (PCI), and patients who received newer-generation DESs since 2010 were analyzed. The primary endpoint was major adverse cardiovascular events (MACEs), and secondary endpoint was all-cause mortality. Of 6242 AMI patients, 5397 were alive 1 year after the index procedure. The cumulative incidence of MACEs and all-cause death 1 to 7 years after AMI were 28.4% (annually 4–6%) and 20.2% (annually 3–4%), respectively. Multivariate analysis showed that uncontrolled systolic blood pressure (SBP) and serum low-density lipoprotein cholesterol (LDL-C) concentration, as well as traditional risk factors, were associated with MACEs and all-cause death. Recurrent non-fatal myocardial infarction, ischemic stroke, and bleeding events within 1 year were significantly associated with all-cause death. The risks of adverse cardiovascular events and death remain high in AMI patients more than 1 year after the index PCI with newer-generation DESs. Traditional risk factors, uncontrolled SBP and LDL-C, and non-fatal adverse events within 1 year after the index procedure strongly influence long-term clinical outcomes.https://www.mdpi.com/2077-0383/10/16/3642acute myocardial infarctiondrug-eluting stentsmortalitypercutaneous coronary interventionprognosis |
| spellingShingle | Sungmin Lim Eun Ho Choo Ik Jun Choi Kwan Yong Lee Su Nam Lee Byung-Hee Hwang Chan Joon Kim Mahn-Won Park Jong-Min Lee Chul Soo Park Hee-Yeol Kim Ki-Dong Yoo Doo Soo Jeon Ho Joong Youn Wook Sung Chung Min Chul Kim Myung Ho Jeong Hyeon Woo Yim Youngkeun Ahn Kiyuk Chang Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents Journal of Clinical Medicine acute myocardial infarction drug-eluting stents mortality percutaneous coronary intervention prognosis |
| title | Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents |
| title_full | Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents |
| title_fullStr | Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents |
| title_full_unstemmed | Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents |
| title_short | Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents |
| title_sort | risks of recurrent cardiovascular events and mortality in 1 year survivors of acute myocardial infarction implanted with newer generation drug eluting stents |
| topic | acute myocardial infarction drug-eluting stents mortality percutaneous coronary intervention prognosis |
| url | https://www.mdpi.com/2077-0383/10/16/3642 |
| work_keys_str_mv | AT sungminlim risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT eunhochoo risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT ikjunchoi risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT kwanyonglee risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT sunamlee risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT byungheehwang risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT chanjoonkim risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT mahnwonpark risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT jongminlee risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT chulsoopark risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT heeyeolkim risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT kidongyoo risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT doosoojeon risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT hojoongyoun risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT wooksungchung risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT minchulkim risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT myunghojeong risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT hyeonwooyim risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT youngkeunahn risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents AT kiyukchang risksofrecurrentcardiovasculareventsandmortalityin1yearsurvivorsofacutemyocardialinfarctionimplantedwithnewergenerationdrugelutingstents |